Evidence map›Paper›PMID 40234394›Full record

ArticleBlood cancer journal2025

Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysis.

Y Sawalha, S Sarosiek, R L Welkie, S Seif, S Thapa, S Zanwar, K Cahill, R Treitman, H Shah, S Arora and 10 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Y SawalhaThe Ohio State University Wexner Medical Center, Columbus, OH, USA. yazeed.sawalha@osumc.edu.ORCID http://orcid.org/0000-0001-6355-3671
S SarosiekBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-0075-6735
R L WelkieThe Ohio State University Wexner Medical Center, Columbus, OH, USA.
S SeifM.D. Anderson Cancer Center, Houston, TX, USA.
S ThapaH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
S ZanwarMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5074-8453
K CahillLoyola University Medical Center, Maywood, IL, USA.
R TreitmanUniversity of Colorado School of Medicine, Denver, CO, USA.
H ShahCleveland Clinic, Cleveland, OH, USA.
S AroraUniversity of California San Francisco, San Francisco, CA, USA.
G PongasUniversity of Miami, Miami, FL, USA.
A WinterCleveland Clinic, Cleveland, OH, USA.
A MajorUniversity of Colorado Cancer Center, Aurora, CO, USA.ORCID http://orcid.org/0000-0001-7261-1335
P A RiedellUniversity of Chicago, Chicago, IL, USA.ORCID http://orcid.org/0000-0003-2719-0580
M L PalombaMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0001-5099-9156
P KapoorMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0002-4342-364X
A Grajales-CruzH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
K H ShainH. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
S K ThomasM.D. Anderson Cancer Center, Houston, TX, USA.
J J CastilloBing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9490-7532

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Venetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively identified 76 patients with relapsed/refractory lymphoplasmacytic lymphoma (LPL)/WM treated with venetoclax monotherapy at nine US medical centers. The median age at venetoclax treatment initiation was 66 years. MYD88, CXCR4, and TP53 mutations were detected in 65 (94%), 23 (40%), and 10 (22%) patients, respectively. The median number of prior lines of treatment was 3, including covalent BTK inhibitor in 82% and alkylating agent in 71% of patients. The overall and major response rates to venetoclax were 70% and 63%, respectively. The median and 2-year progression-free survival (PFS) were 28.5 months and 57%, respectively. The median and 2-year overall survival were not reached and 82%, respectively. Prior treatment with BTK inhibitor was the only factor associated with PFS in multivariate analysis (hazard ratio 2.97, p = 0.012). Venetoclax dose interruptions and/or reductions occurred in 27 patients (41%). Five patients (7%) developed laboratory tumor lysis syndrome (TLS), including 3 (4%) with clinical TLS. Venetoclax resulted in a high response rate and a prolonged PFS in patients with heavily pretreated LPL/WM.

Indexed as

Antineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicSulfonamidesWaldenstrom MacroglobulinemiaAgedAged, 80 and overFemaleHumansMaleMutationMyeloid Differentiation Factor 88PrognosisReceptors, CXCR4Retrospective StudiesTreatment OutcomeAntineoplastic AgentsBridged Bicyclo Compounds, HeterocyclicMYD88 protein, humanMyeloid Differentiation Factor 88Receptors, CXCR4Sulfonamidesvenetoclax

Identifiers

PMID40234394
PMCPMC12000436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.